Gyre Therapeutics (GYRE) reported Q3 earnings Wednesday of $0.01 per diluted share, down from $0.05 a year earlier.
Revenue for the quarter ended Sept. 30 was $25.5 million, down from $32 million a year earlier.
Analysts' estimates were not readily available for comparison.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。